ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2107

Therapeutic Response to Prednisone in Relation to Age in Polymyalgia Rheumatica: A Controlled Study

Aline Charpentier1, Frank Verhoeven2,3, Maxime Sondag1, Xavier Guillot4, Clément Prati5 and Daniel Wendling6, 1rheumatology, CHU de Besançon, Besancon, France, 2EA 4267 FDE, FHU INCREASE, Université de Bourgogne Franche-Comté, Besançon, France, 3Service de Rhumatologie, CHRU J Minjoz, Besançon, France, 4EA 4267 FDE, FHU INCREASE, Université de Bourgogne FrancheComté, Besançon, France, 5Service de Rhumatologie, CHU J Minjoz, Besancon, France, 6Service de Rhumatologie, CHU Jean Minjoz, Besancon, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Polymyalgia rheumatica and prognostic factors

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disorder which usually affect patients over 65 years old. Different poor prognostic factors are involved in prednisone response including rapid decrease of prednisone dose or female sex. To date, there is no data relating the impact of the age on therapeutic response in PMR. The aim of this study was to compare, in case of PMR, the response to prednisone in patients younger than 60 to patients over 65 years old.

Methods:

This was a retrospective, monocentric study. We included patients with PMR, meeting ACR 2012 criteria. Patients were classified into two groups, one group with patients less than 60 years, and one group with patients over 65 years. We registered demographic, clinical, biological, and imaging data as well as therapeutic response profile. The local inflammation was evaluated with PET scan, by studying each anatomical site usually affected by PMR. Then, the rate of inflammation was scored from 0 to 3, according to the intensity of uptake compared to liver. The treatment was standardized. The initial dose of prednisone was of 0.3mg/kg/j during the two first weeks, then, the dose was slowly decreased by 10 % each month. The main endpoint was a steroid dependence defined by the recurrence of PMR symptoms and / or the increase of CRP at two times during the decrease of prednisone.

Results:

We included 14 patients younger than 60 years old (average age 54+/- 0.8 years) and 28 patients older than 65 years old (average age 75.8 +/- 1.5 years). The population younger than 60 years was mainly male (60% VS 27 %, p<0.05). Both groups were similar in terms of morning stiffness (2,1 ± 0,4 VS 1,9 ± 0,3 hours; p>0.05), disease duration (4,2 ± 0,8 VS 4,1 ± 0,6 months; p>0.05), leukocytes rate (8,3 ± 1,37 VS 8 ± 0,7 G/L; p>0.05) and percentage of antinuclear antibodies rate over 1/320 (20 % VS 10%; p>0.05). However, regarding to local inflammation, the intensity of FDG uptake highlighted by the Pet scan was lower among young patients (score of 16,9 ± 1,7 VS 26,5 ± 3,0; p<0.05). Furthermore, we observed a significant difference concerning therapeutic response according to the age: 60% of the young patients developed a steroid dependence compared to20% in group of old patients (p<0.05). Moreover, the introduction of methotrexate was necessary for 35% of the young patients against 6.5% (p<0.05).

Conclusion:

Our study is the first to show the age as a bad prognosis factor in case of PMR. This difference is independent to the systemic and local inflammation (assessed by the PET score) is more important in elderly people. Young patients with PMR are mostly men and are more dependent on steroids. Thus, methotrexate could be straightaway proposed, particularly in patient younger than 60 years old.


Disclosure: A. Charpentier, None; F. Verhoeven, None; M. Sondag, None; X. Guillot, None; C. Prati, None; D. Wendling, None.

To cite this abstract in AMA style:

Charpentier A, Verhoeven F, Sondag M, Guillot X, Prati C, Wendling D. Therapeutic Response to Prednisone in Relation to Age in Polymyalgia Rheumatica: A Controlled Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/therapeutic-response-to-prednisone-in-relation-to-age-in-polymyalgia-rheumatica-a-controlled-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/therapeutic-response-to-prednisone-in-relation-to-age-in-polymyalgia-rheumatica-a-controlled-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology